DFTX Share Price Performance
US$47.07
39.01 (484.00%)
35.3% undervalued intrinsic discount
US$72.73
Fair Value
Price US$47.07
AnalystHighTarget US$72.73
AnalystConsensusTarget US$35.23
AnalystLowTarget US$35.66
Fair ValueUS$72.73
Share Pricen/a
Definium Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 84 Fair Values set on narratives written by author
DFTX Community Narratives
AN
Fair Value
·Fair Value US$72.73 35.3% undervalued intrinsic discount
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$35.23 33.6% overvalued intrinsic discount
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$35.66 32.0% overvalued intrinsic discount
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Read more
AN
US$72.73
35.3% undervalued intrinsic discount
Fair Value
Profit Margin
53.62%
Future PE
15.77x
Price in 2029
US$0
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Definium Therapeutics is racing to prove a psychedelic-based treatment in late-stage studies, but a few trial disappointments or delays could quickly change the story. Even if the drug works, the need for supervised dosing and extra safety steps could make rollout slow and expensive, testing whether this can become a real business.Read more
AN
US$35.66
32.0% overvalued intrinsic discount
Fair Value
Profit Margin
19.65%
Future PE
1.84kx
Price in 2029
US$0
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?Read more
AN
US$35.23
33.6% overvalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
126.88x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
DFTX: Phase 3 Depression Data Will Drive Repricing Of Psychedelic Franchise
Fair Value: US$72.73 35.3% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DFTX: Phase 3 Depression Data Will Likely Prove Priced In
Fair Value: US$35.66 32.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Fair Value: US$35.23 33.6% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Definium Therapeutics, Inc. Key Details
About DFTX
- Founded
- n/a
- Employees
- 106
- CEO
- WebsiteView website
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
